|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Cachexia, secondary to HIV |
|
Growth failure, secondary to chronic renal failure |
|
Growth failure, secondary to growth hormone deficiency |
|
Growth failure, secondary to Prader- Willi syndrome |
|
Growth failure, secondary to small for gestational age |
|
Growth hormone deficiency |
|
Short bowel syndrome |
|
Short stature, idiopathic |
|
Short stature, secondary to Turner syndrome |
|
Wasting, secondary to HIV |
| |
|
|
SIDE EFFECTS:
|
|
Otitis media or other ear disorders |
|
Allergic reaction |
|
intracranial hypertension |
|
lipodystrophy at site of injection |
|
pain and swelling at site of injection |
|
pancreatitis |
|
slipped capital femoral epiphysis |
|
Carpal tunnel syndrome |
|
gynecomastia |
|
headache |
|
increased growth of nevi |
|
joint pain |
|
muscle pain |
|
peripheral edema |
|
unusual tiredness or weakness |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Diabetes mellitus |
|
>> Hypothyroidism, untreated |
|
Malignancy, especially intracranial tumor, actively growing within the previous 12 months |
|
|
ADULT DOSE:
|
|
Growth hormone deficiency-associated growth failure -Nutropin AQ-Initial-
Subcutaneous, up to 0.006 mg (0.018 IU) per kg of body weight a day.
Maintenance, titrated based on insulin-like growth factor-I (IGF-I) concentration and the occurrence of side effects -
Patients up to 35 years of age: Subcutaneous, up to 0.025 mg (0.075 IU) per kg of body weight a day.
Patients 35 years of age or older: Subcutaneous, up to 0.0125 mg (0.0375 IU) per kg of body weight a day. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Deficiency (prophylaxis)-
Oral, amount based on normal daily recommended intakes of elemental iron:
Persons U.S. Canada
(mg) (mg)
Infants and children 6-10 0.3-6
Birth to 3 years of age
4 to 6 years of age 10 8
7 to 10 years of age 10 8-10
Deficiency (treatment)-
Treatment dose is individualized by prescriber based on severity of deficiency. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|